Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros Therapeutics Inc. - RPRX

RPRX

The Rosen Law Firm announces that it is investigating potential securities claims against Repros Therapeutics Inc. (NASDAQ: RPRX) resulting from allegations that the Company may have issued materially misleading business information to the investing public.

Repros Therapeutics is a development stage biopharmaceutical company with a focus on developing new drugs to treat hormonal and reproductive system disorders. Its product portfolio includes Androxal, which treats low testosterone due to secondary hypogonadism. On September 26, 2014, Repros Therapeutics announced that the FDA granted the Company a Type B Pre-New Drug Application (Pre-NDA) meeting in the first half of November. The Company planned on seeking guidance on its planned new drug application for Androxal at this meeting. On October 17, 2014, Repros Therapeutics revealed that the clinical information provided was insufficient for a Type B Pre-NDA meeting. Rather, a Type C Guidance meeting would be held instead. On this news, shares of Repros Therapeutics fell sharply during intraday trading on October 17, 2014, damaging investors.

The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Repros Therapeutics shareholders as a result of this adverse information. If you purchased Repros Therapeutics stock on or before October 17, 2014, please visit the website at http://rosenlegal.com/cases-402.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today